{"id":"595543bc-6e39-470e-88f0-b10048b106c7","arxiv_id":"2507.07426","paper_version":3,"verdict":"CONDITIONAL","confidence":"HIGH","novelty_score":6.0,"correctness_risk":"medium","formal_verification":"none","parameter_count":6,"one_line_summary":"A multi-agent, retrieval-augmented search framework lets a 7B language model outperform larger baselines on drug-target interaction prediction, but its headline recall relies on knowing the ground-truth output count.","lead":"DrugMCTS combines five AI agents with Monte Carlo Tree Search to guess which proteins a drug molecule might hit, using retrieval from chemistry databases instead of retraining. On two drug-target benchmarks it reports higher recall than larger general-purpose models and deep learning baselines, though the evaluation gives the model the number of correct answers to output.","discovery_kind":"new_application","skeptic_critique":{"model":"deepseek-v4-flash","headline":"Ground-truth-aware output budgets make the TopK+3 headline incomparable; an equal-budget re-run is needed.","rationale":"The reader identifies the ground-truth-aware output budget as the weakest assumption, and my reading converges on the same point. The framework is described in enough detail to be reconstructable, the ablation in Table 2 is internally consistent, and the Selection = GT count row still beats the DL ensemble by a wide margin on DrugBank (44.66% vs 23.64%), so there is a credible core result. But the number advertised in the abstract and conclusion (55.34% via TopK+3) depends on giving DrugMCTS three extra output slots that the baselines do not receive, while the method is told the true interaction count. This is the most load-bearing flaw because it directly targets the claimed superiority over Deepseek-R1 and the deep-learning baselines. The limitations section even concedes that the absolute reward adds only about 1%, so the marginal MCTS reward design is not the decisive issue; the evaluation protocol is. A single equal-budget experiment would settle whether the headline gain is real. The reader's CONDITIONAL verdict already reflects this risk, so I do not propose a change to the verdict.","tokens_in":12228,"tokens_out":7352,"duration_ms":84003,"concrete_test":"Re-run the DrugBank and KIBA comparisons under a single fixed, pre-specified output budget K (e.g., K=5) applied identically to DrugMCTS, GPT-4o-mini, Deepseek-R1, and the DL ensemble, reporting recall@K and precision@K. Then, as a second arm, re-run the advertised TopK+3 condition while also allowing every baseline to output k+3 proteins. If DrugMCTS's advantage over the DL baselines collapses at equal K, or if the baselines match it when given the same k+3 budget, the headline superiority claim is an artifact of the ground-truth-aware output count and should be withdrawn in favor of the equal-budget result.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The headline result in Section 3.4 (Table 1) is built on output counts that are derived from the ground-truth labels. The DL baselines choose the top-k proteins with k equal to the true number of interacting proteins, and DrugMCTS is run with 'Selection = GT count' or 'Selection = GT + 3'. Knowing k at inference is an oracle assumption: a real repurposing pipeline does not know how many true targets a drug has. The advertised TopK+3 condition is also not comparable to the baselines: DrugMCTS is allowed k+3 predictions while baselines are capped at k, and recall is nondecreasing in the number of outputs because the denominator is fixed. From the dataset statistics in Table 4, the average ground-truth size is about 2 and the average candidate pool is about 19 proteins, so increasing the output budget from k to k+3 raises random-chance recall from roughly 11% to roughly 27% on DrugBank. Thus part or all of the measured +10.7-point DrugBank gain (0.4466 to 0.5534) and +7.0-point KIBA gain (0.4224 to 0.4924) may be a budget effect rather than better ranking. The paper never reports precision@K, recall at a fixed K, or a baseline run with the same k+3 budget, so this cannot be adjudicated from the table. The fair row (Selection = GT count) still shows a substantial improvement over the deep-learning baselines, so the framework is not refuted; but the specific abstract/conclusion claim built on 55.34% recall is not supported until the comparison is equalized.","agreement_with_reader":"agree"},"referee_report":{"model":"deepseek-v4-flash","summary":"The paper proposes DrugMCTS, a drug repurposing framework that combines retrieval-augmented generation, five specialized LLM agents, and Monte Carlo Tree Search to predict protein targets for a query molecule without fine-tuning. The framework first retrieves similar molecules and their associated proteins, then uses a sequence of analysis, selection, and decision agents to build reasoning paths, with MCTS selecting among candidate proteins. The authors evaluate on DrugBank and KIBA, reporting that DrugMCTS with a TopK output strategy achieves 44.66% recall on DrugBank and 42.24% on KIBA, and that a TopK+3 output strategy reaches 55.34% and 49.24%, respectively, outperforming GPT-4o-mini, Deepseek-R1, and a four-model deep learning ensemble. The paper also includes ablations and a case study on Equol-CXCR3.","tokens_in":12598,"tokens_out":2974,"duration_ms":34621,"significance":"If the reported results survive scrutiny, the paper would make a useful contribution: it packages multi-agent RAG with MCTS in a relatively lightweight 7B model, avoids fine-tuning, and reports an interpretable, step-by-step reasoning pipeline. The framework is clearly described, and the ablation study showing that the MCTS process contributes beyond richer prompting is interesting. However, the central empirical claim is currently undermined by the way output budgets are chosen: the headline TopK+3 condition gives DrugMCTS three extra predictions relative to the deep learning baselines, and both the TopK and TopK+3 conditions assume knowledge of the ground-truth interaction count. The fair comparison row (Selection = GT count) still shows a real gap over baselines, so the framework is not refuted, but the specific numbers advertised in the abstract and conclusion are not yet supported. The reward function is also entirely model-internal, so the 'feedback-driven search' is more naturally interpreted as optimizing self-consistency than as optimizing biologically valid interactions.","major_comments":[{"comment":"The headline result 'Selection = GT + 3' is not comparable to the baselines. Deep learning baselines output exactly k proteins with k equal to the ground-truth interaction count, while DrugMCTS is allowed k+3 outputs. Since recall has a fixed denominator, adding outputs cannot decrease recall and typically increases it; from the dataset statistics in Appendix Table 4, the expected random-chance recall on DrugBank rises from roughly 11% to roughly 27% when the budget grows from k to k+3. The paper reports no precision@K, no recall at a fixed K, and no baseline run with a k+3 budget, so the advertised +10.7-point DrugBank gain and +7.0-point KIBA gain may be in large part a budget effect. I ask for an equal-budget comparison (e.g., precision@K or recall at a fixed K for all systems), plus a version of Table 1 that clearly separates output-count effects from ranking quality.","section":"§3.3 and §3.4, Table 1"},{"comment":"The evaluation protocol assumes the number of true targets is known at inference time. Both 'Selection = GT count' and 'Selection = GT + 3' use the ground-truth interaction count to determine how many proteins DrugMCTS outputs, and the deep learning baselines are also instructed to choose top-k with k equal to the ground-truth length (Section 3.3). This is an oracle assumption: a real drug repurposing pipeline does not know in advance how many proteins a drug interacts with. The fair row (Selection = GT count) still shows a substantial improvement, but the abstract and conclusion claim built on 55.34% recall is not attainable under realistic deployment conditions. I request a non-oracle variant, for example fixing the output count to a constant or to a value estimated from the candidate pool, and reporting both recall and precision under that protocol.","section":"§2.4, Eqs. (4)-(6)"},{"comment":"The MCTS reward is computed entirely from the same LLM's outputs: the relative reward is the frequency with which the model itself selects a protein across repeated queries, and the absolute reward is the model's own yes/no rate on its own proposal. The search therefore optimizes the model's self-consistency rather than any external signal of true interaction. This is not by itself a fatal flaw, but it does mean the reported gains over baselines do not establish that the MCTS mechanism is learning biologically valid interactions; it may simply be selecting answers the model is internally confident about. The paper's own ablation (S6 vs. full reward, Table 2) shows that the absolute reward adds only about 1% over relative-only, which reinforces this concern. I ask for either an external reward signal (e.g., docking scores or a held-out classifier) or a direct analysis of how reward values correlate with ground-truth correctness.","section":"§4.2, Table 2"},{"comment":"The ablation protocol changes the output count between conditions in a way that can confound the ablation comparisons. Section 4.1 states that MCTS-based baselines generate four candidate nodes during Protein Selection 'to ensure fair comparison', whereas Section 3.2 says the full pipeline generates only one node for protein selection. Since recall depends on the number of outputs, a condition that emits four proteins will have a mechanical advantage over one that emits one protein. Please report the output count used in each ablation row, or fix the output budget across all rows, so the component-wise drops are not explainable by node-count differences.","section":"§3.3"},{"comment":"The deep learning baseline protocol itself also uses oracle output counts: 'choosing the top-k proteins, where k corresponds to the length of the ground truth.' This makes the baseline numbers optimistic relative to any real deployment, but it is still a reasonable upper-bound baseline. The main problem is that DrugMCTS is given either the same oracle count or a larger oracle-based count, so the comparison does not isolate ranking quality. This is a load-bearing issue for the central claim and should be addressed with the equal-budget experiments described above.","section":"§5"}],"minor_comments":[{"comment":"The text says RAG prompting made GPT-4o-mini 'drop' from 16.19% to 15.19%, but the zero-shot value in Table 1 is 15.52%; the language should be corrected to describe the actual small decrease or increase.","section":"§3.4"},{"comment":"The caption contains a typo: 'pipeline' is misspelled as 'pipeline'.","section":"Figure 2"},{"comment":"The sentence 'although the other three methods showed improved performance on the KIBA dataset' does not match Table 1, where some baseline values decrease (e.g., Deepseek-R1 RAG is lower than its zero-shot value). Please rephrase to describe the actual comparison.","section":"§3.4"},{"comment":"The ablation table caption reads 'Top-k/Top-k+3 accuracy', but the table and text report recall, not accuracy; the caption should be corrected.","section":"§4.2"},{"comment":"The limitations section acknowledges that the combined reward adds only about 1% over relative-only, which is useful honesty, but the statement should be reconciled with the stronger claims about the reward mechanism in the introduction and conclusion.","section":"§6"}],"recommendation":"major_revision","confidential_remarks":"The core framework is interesting and the fair GT-count row suggests genuine gains, but the paper's advertised numbers depend on output-budget choices that are either oracle-based or unequal across systems. The self-consistency-based reward also weakens the mechanistic claim of the MCTS component. These issues are fixable with additional experiments, but they are central to the paper's claims, so I recommend major revision rather than acceptance. I do not see evidence of deliberate misrepresentation; the issues are methodological and presentation-level, though they are load-bearing."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"One thing to know: this paper does something genuinely new—it wires MCTS around a multi-agent RAG pipeline for drug-target prediction—and the fair (GT-count) comparison still shows a real gain over deep-learning baselines. The headline number, though, is propped up by a ground-truth-aware output budget and should not be taken at face value.\n\nWhat is actually new: the integration of MCTS with five specialized agents, plus a structured→hybrid→text data-processing pipeline that is reusable beyond this task. The individual components are well-known, but the combination is new, and the ablation studies give some evidence that each module contributes. The case study is a nice touch, and the framework is described in enough detail to reproduce.\n\nSoft spots, in order of importance. The TopK+3 condition in Table 1 lets DrugMCTS output GT+3 predictions while the DL baselines are capped at GT. Given an average ground-truth size of about 2 and a candidate pool of about 19 proteins, that extra budget alone could explain most of the +10.7-point gain on DrugBank. The paper never reports precision at a fixed K or a baseline with the same k+3 budget, so that gain is uninterpretable. The GT-count selection itself is an oracle assumption: in practice you do not know how many true targets a drug has. The MCTS reward is a self-consistency loop—both the relative and absolute rewards are computed from the same LLM's own outputs—so the 'feedback' is optimizing self-agreement, not an external signal. The absolute reward adds only about 1% over the relative-only variant, which undercuts its role. No error bars, and the dataset is only 788 and 626 entries.\n\nWho this is for: people building LLM-driven drug repurposing systems. It is a useful integration, and the fair comparison (Selection = GT count) still shows a substantial improvement over the DL baselines, so the core idea has legs. But the evaluation protocol needs to be corrected—equal output budgets for all methods, plus precision@K—before the superiority claim is credible.\n\nRecommendation: send it to peer review, but with a clear request to redo the evaluation with matched output budgets and to report variance. It is not a desk reject; it is a major-revision.","headline":"A useful new integration of MCTS with multi-agent RAG for drug repurposing, but the headline recall number is inflated by a ground-truth-aware output budget; the fair comparison still looks strong.","tokens_in":13133,"tokens_out":2942,"would_cite":true,"duration_ms":31214,"reading_group":"yes","serious_thinker":"yes","would_accept_peer_review":true},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"DrugMCTS claims that a lightweight 7-billion-parameter model, guided by five specialized agents and Monte Carlo Tree Search, achieves 55.34% recall on DrugBank and 49.24% on KIBA, surpassing larger LLMs and deep learning baselines without…","keywords":["drug repurposing","Monte Carlo Tree Search","multi-agent LLM","retrieval-augmented generation","drug-target interaction prediction","LLM reasoning","DrugBank","KIBA"],"falsifier":"Re-run the DrugBank and KIBA evaluations with a fixed output budget for every method, for example exactly five proteins per drug, and compare recall and precision@k; if DrugMCTS no longer beats the deep-learning ensemble and the zero-shot LLMs by the reported margins, the headline result depends on oracle knowledge of the answer-set size.","tokens_in":12011,"feed_emoji":"💊","tokens_out":10884,"duration_ms":104561,"temperature":0.7,"pith_summary":"This paper argues that drug-target interaction prediction can be substantially improved by replacing one-shot LLM prompting with a structured, search-guided pipeline. The proposed DrugMCTS system sends a query molecule through five agents that retrieve similar molecules, analyze physicochemical properties, filter candidates, and inspect binding pockets, while Monte Carlo Tree Search explores and scores alternative reasoning paths. On the DrugBank and KIBA benchmarks it reports a recall of 44.66% and 42.24% under a base top-k rule, rising to 55.34% and 49.24% when the selection budget is set to the ground-truth interaction count plus three. The core message is that inference-time search and agent collaboration can let a 7-billion-parameter model outperform far larger zero-shot LLMs and trained deep learning models without fine-tuning.","feed_headline":"Search-guided agents lift drug-target recall to 55.34%","feed_subtitle":"A 7B-parameter model with five agents and tree search needs no fine-tuning to beat larger LLMs.","key_machinery":"The load-bearing machinery is the combination of five specialized LLM agents with Monte Carlo Tree Search. The Retrieval Agent builds a candidate molecule pool by Tanimoto similarity and ChemBERTa cosine similarity; the Molecule-Analysis Agent converts RDKit and PubChem properties into a textual report; the Molecule-Selection Agent filters candidates for pharmacophore integrity and drug-likeness; the Interaction-Analysis Agent extracts binding-pocket descriptors from PDB files with PLIP and adds PubMed literature; and the Decision Agent selects the predicted target. MCTS selects, expands, simulates, and backpropagates over these agent actions using the UCT rule, with a final reward that averages a self-consistency score and an absolute 'yes' frequency from repeated model queries.","core_discovery":"On the paper's own terms, the discovery is that retrieval-augmented multi-agent reasoning becomes decisively more accurate once Monte Carlo Tree Search is wrapped around it, and that this makes domain-specific fine-tuning unnecessary for competitive drug repositioning. With Qwen2.5-7B-Instruct as the backbone, DrugMCTS achieves a recall of 44.66% on DrugBank and 42.24% on KIBA using a base TopK rule, and 55.34% and 49.24% with TopK+3 dynamic selection, surpassing Deepseek-R1, GPT-4o-mini, and an ensemble of four deep learning models. Ablations attribute the largest gain to MCTS itself, with the molecule-analysis and interaction-analysis agents contributing several points each and the absolute reward component adding only about one point.","pith_inferences":["Inference: on a genuinely new drug with unknown targets, the selection budget cannot be set to ground truth; comparing methods with precision@k, NDCG, or a calibrated confidence threshold would test whether the reported advantage carries over to practice.","Inference: the candidate protein pool is built from molecules structurally similar to the query, so on a novel scaffold with few close analogues in the database, the retrieval stage itself becomes the bottleneck and the reported recall upper bound may not transfer.","Inference: replacing the self-consistency reward with a structure-based docking score is a natural next step the authors do not test; their own case study uses docking only as post hoc validation."],"forward_implications":["A 7B-parameter model with inference-time search can replace domain fine-tuning for drug-target interaction prediction, cutting training cost and avoiding retraining-driven forgetting.","MCTS plus agent-based filtering becomes a reusable recipe for making retrieval-augmented generation robust to noisy or long-context scientific input, addressing the 'lost in the middle' failure.","The absolute reward contributes little (about 1% in ablations), so future gains should come from better reward signals; performance also plateaus after roughly 12 rollouts, bounding the compute-recall trade-off.","Because the TopK+3 rule uses ground-truth target counts, operational deployment needs a separate mechanism for deciding how many proteins to output, or a ranking-based evaluation."],"supporting_citations":[{"why":"supplies the DrugBank benchmark dataset used for the main recall comparison.","marker":"[12]"},{"why":"supplies the KIBA benchmark dataset used for the main recall comparison.","marker":"[25]"},{"why":"defines the Qwen2.5-7B-Instruct backbone that achieves the reported results without fine-tuning.","marker":"[26]"},{"why":"is the Deepseek-R1 reasoning LLM baseline that DrugMCTS is claimed to surpass.","marker":"[7]"},{"why":"provides the DrugRealign methodology for extracting binding-pocket text that the Interaction-Analysis Agent adapts.","marker":"[29]"},{"why":"supplies the self-consistency scoring method used as the relative reward in MCTS.","marker":"[28]"},{"why":"defines the continuous UCT algorithm used for node selection in Monte Carlo Tree Search.","marker":"[5]"},{"why":"is the AttentionDTA deep-learning baseline included in the ensemble comparison.","marker":"[37]"},{"why":"is the GraphDTA deep-learning baseline included in the ensemble comparison.","marker":"[21]"},{"why":"is the DeepConv-DTI deep-learning baseline included in the ensemble comparison.","marker":"[13]"}],"fun_headline_variants":["DrugMCTS boosts drug repurposing recall to 55% with tree search","Multi-agent tree search beats fine-tuning for drug repurposing","No fine-tuning: MCTS agents hit 55% recall on DrugBank","Tree-search agents outperform larger LLMs in drug repositioning","DrugMCTS: five agents plus tree search lift recall to 55%"],"cache_read_input_tokens":3200,"weakest_assumption_plain":"The reported recall numbers assume that the number of true target proteins for each query is known in advance, because DrugMCTS and the baselines set their output count to the ground-truth count or the ground-truth count plus three.","fun_headline_variants_meta":{"raw":{"variants":["DrugMCTS boosts drug repurposing recall to 55% with tree search","Multi-agent tree search beats fine-tuning for drug repurposing","No fine-tuning: MCTS agents hit 55% recall on DrugBank","Tree-search agents outperform larger LLMs in drug repositioning","DrugMCTS: five agents plus tree search lift recall to 55%"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.000396,"raw_usage":{"total_tokens":2042,"prompt_tokens":878,"completion_tokens":1164,"prompt_tokens_details":{"cached_tokens":384},"prompt_cache_hit_tokens":384,"prompt_cache_miss_tokens":494,"completion_tokens_details":{"reasoning_tokens":1069}},"tokens_in":494,"tokens_out":1164,"duration_ms":9062,"temperature":1.0,"reasoning_tokens":1069,"cache_read_input_tokens":384,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-06T18:41:27.903269+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"Re-run the DrugBank and KIBA evaluations with a fixed output budget for every method, for example exactly five proteins per drug, and compare recall and precision@k; if DrugMCTS no longer beats the deep-learning ensemble and the zero-shot LLMs by the reported margins, the headline result depends on oracle knowledge of the answer-set size.","supporting_citations":[{"cited_title":"Drugbank 6.0: the drugbank knowledgebase for 2024","cited_arxiv_id":null,"evidence_quote":"supplies the DrugBank benchmark dataset used for the main recall comparison."},{"cited_title":"Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and in- tegrative analysis","cited_arxiv_id":null,"evidence_quote":"supplies the KIBA benchmark dataset used for the main recall comparison."},{"cited_title":"Drugrealign: a multisource prompt framework for drug repurposing based on large language models","cited_arxiv_id":null,"evidence_quote":"provides the DrugRealign methodology for extracting binding-pocket text that the Interaction-Analysis Agent adapts."},{"cited_title":"Continuous upper confidence trees","cited_arxiv_id":null,"evidence_quote":"defines the continuous UCT algorithm used for node selection in Monte Carlo Tree Search."},{"cited_title":"Attentiondta: prediction of drug– target binding affinity using attention model","cited_arxiv_id":null,"evidence_quote":"is the AttentionDTA deep-learning baseline included in the ensemble comparison."},{"cited_title":"Graphdta: predicting drug–target binding affin- ity with graph neural networks","cited_arxiv_id":null,"evidence_quote":"is the GraphDTA deep-learning baseline included in the ensemble comparison."},{"cited_title":"Deepconv-dti: Prediction of drug-target interac- tions via deep learning with convolution on pro- tein sequences","cited_arxiv_id":null,"evidence_quote":"is the DeepConv-DTI deep-learning baseline included in the ensemble comparison."}],"review_version":1}